MASLD-Related Hepatocarcinoma: Special Features and Challenges

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Aug 29

PMID 39200802

Authors

Carmen Yague-Caballero

Diego Casas-Deza

Andrea Pascual-Oliver

Silvia Espina-Cadena

Jose M Arbones-Mainar

Vanesa Bernal-Monterde

Affiliations

Soon will be listed here.

Abstract

Metabolic-associated steatohepatitis liver disease (MASLD) currently impacts a quarter of the global population, and its incidence is expected to increase in the future. As a result, hepatocellular carcinoma associated with MASLD is also on the rise. Notably, this carcinoma does not always develop alongside liver cirrhosis, often leading to a more advanced stage at diagnosis. The challenge lies in accurately identifying patients who are at a higher risk to tailor screening processes effectively. Additionally, several therapeutic approaches are being explored to prevent hepatocellular carcinoma, although there are no universally accepted guidelines yet.

References

Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T . Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021; 56(11):1022-1032. PMC: 8531127. DOI: 10.1007/s00535-021-01828-6. View

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

Ludwig J, Viggiano T, MCGILL D, Oh B . Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55(7):434-8. View

Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva G, Giannini E . Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut. 2021; 72(1):141-152. DOI: 10.1136/gutjnl-2021-324915. View

Vetrano E, Rinaldi L, Mormone A, Giorgione C, Galiero R, Caturano A . Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. Biomedicines. 2023; 11(2). PMC: 9953066. DOI: 10.3390/biomedicines11020468. View

Han S, Baik S, Kim M . Non-alcoholic fatty liver disease: Definition and subtypes. Clin Mol Hepatol. 2022; 29(suppl):S5-S16. PMC: 10029964. DOI: 10.3350/cmh.2022.0424. View

Gariani K, Jornayvaz F . Pathophysiology of NASH in endocrine diseases. Endocr Connect. 2021; 10(2):R52-R65. PMC: 7983516. DOI: 10.1530/EC-20-0490. View

Kim D, Touros A, Kim W . Nonalcoholic Fatty Liver Disease and Metabolic Syndrome. Clin Liver Dis. 2017; 22(1):133-140. DOI: 10.1016/j.cld.2017.08.010. View

Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y . Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9(5):428-33. DOI: 10.1016/j.cgh.2011.01.023. View

10.

Guan M, Zhang S, Ding Q, Li N, Fu T, Zhang G . The Performance of GALAD Score for Diagnosing Hepatocellular Carcinoma in Patients with Chronic Liver Diseases: A Systematic Review and Meta-Analysis. J Clin Med. 2023; 12(3). PMC: 9918029. DOI: 10.3390/jcm12030949. View

11.

Shah P, Patil R, Harrison S . NAFLD-related hepatocellular carcinoma: The growing challenge. Hepatology. 2022; 77(1):323-338. PMC: 9970023. DOI: 10.1002/hep.32542. View

12.

Baumeister S, Schlesinger S, Aleksandrova K, Jochem C, Jenab M, Gunter M . Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study. J Hepatol. 2018; 70(5):885-892. DOI: 10.1016/j.jhep.2018.12.014. View

13.

Zhou X, Targher G, Byrne C, Somers V, Kim S, Chahal C . An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023; 17(4):773-791. PMC: 10198034. DOI: 10.1007/s12072-023-10543-8. View

14.

Huang D, El-Serag H, Loomba R . Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2020; 18(4):223-238. PMC: 8016738. DOI: 10.1038/s41575-020-00381-6. View

15.

Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M . Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Int J Mol Sci. 2020; 21(4). PMC: 7073210. DOI: 10.3390/ijms21041525. View

16.

Cagnin S, Donghia R, Martini A, Pesole P, Coletta S, Shahini E . Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma. Int J Mol Sci. 2023; 24(22). PMC: 10671761. DOI: 10.3390/ijms242216485. View

17.

Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S . Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. Clin Gastroenterol Hepatol. 2016; 14(6):875-886.e6. DOI: 10.1016/j.cgh.2015.12.042. View

18.

Verdelho Machado M . The Growing Landscape of NAFLD-Associated Hepatocellular Carcinoma and Its Impact in Surveillance. GE Port J Gastroenterol. 2024; 31(1):14-23. PMC: 10836954. DOI: 10.1159/000531397. View

19.

Taru M, Lupsor-Platon M . Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound Elastography. Cancers (Basel). 2023; 15(16). PMC: 10452922. DOI: 10.3390/cancers15164097. View

20.

McGlynn K, Petrick J, El-Serag H . Epidemiology of Hepatocellular Carcinoma. Hepatology. 2020; 73 Suppl 1:4-13. PMC: 7577946. DOI: 10.1002/hep.31288. View